Genetron Holdings Limited (“Genetron Health” or the “Company”,
NASDAQ: GTH), a leading precision oncology platform company in
China that specializes in offering molecular profiling tests, early
cancer screening products and companion diagnostics development,
today reported its unaudited preliminary financial results for the
third quarter ended September 30, 2021.
Third Quarter and Recent
Highlights
- Financials:
- Recorded total revenue of RMB 152.5 million (US $23.7 million)
for the third quarter of 2021, representing a 36.2% increase over
the same period of 2020
- LDT revenue was RMB 93.0 million (US $14.4 million) in the
third quarter of 2021, representing 30.2% growth compared to the
prior year period
- IVD revenue was RMB 51.3 million (US $8.0 million) in the third
quarter of 2021, representing 70.5% growth compared to the prior
year period
- Achieved gross margin of 69.0% for the third quarter 2021
compared to 62.2% in the same period of 2020, primarily driven by
improvements in both the LDT and IVD business lines
- Early screening franchise update:
- Genetron has broadened its registrational strategy for its
early screening program for hepatocellular carcinoma (HCC). The
Company has initiated enrollment for a PCR-based trial in November,
with plans to enroll the NGS-based trial in the next few months.
Genetron anticipates potential NMPA approvals for both assays in
2023
- Developed a multi-omics blood-based CRC early screening assay,
which was trained in a retrospective cohort of 100 cases and 100
controls, and validated in an independent cohort of the same size.
The assay achieved >91% sensitivity with the specificity of 95%.
Full details are planned to be released through a publication in
2022
- MRD franchise update:
- Formed a co-development agreement with AstraZeneca R&D
China for personalized MRD tests for solid tumors in China. Our
partner plans to incorporate the co-developed tests for
China-specific studies. This is an exclusive, multi-year
collaboration (see detailed release here)
- Entered into an exclusive agreement with Fosun Pharma to
commercialize Seq-MRD® in China, marking the Company’s first
product launch for hematologic cancer and MRD detection
- Publications:
- Early Screening: Clinical results and technology findings of
Genetron Health’s early liver cancer screening product for
hepatocellular carcinoma (HCC), HCCscreen™, were included in an
expert consensus and was published in the Chinese Journal of
Hepatology, an influential publication among liver physicians in
China
- MRD: Journal of Hematology & Oncology published an analysis
of a personalized MRD assay developed based on Mutation Capsule
technology. The assay has shown excellent sensitivity to detect
0.001% tumor DNA from peritoneal lavage fluid samples for precise
prediction of peritoneal dissemination in gastric cancer
patients
- Bioinformatics: Briefings in Bioinformatics published enhanced
variant caller performance data that was achieved by Genetron
Health’s bioinformatics team
- Others:
- Established a strategic partnership with NeoGenomics (Nasdaq:
NEO) to drive global oncology drug R&D as well as with IMPACT
Therapeutics to drive development of a synthetic lethal product
pipeline
- Obtained CE Mark for Onco PanScan™, the Company’s large panel
product that covers over 800 genes
“Despite COVID’s impact on our third quarter
financial results, we achieved strong year-over-year revenue growth
of 36.2%, marked by more than 70% increase in our in-hospital (IVD)
sales along with significant gross margin improvement.
Operationally, we’ve had many positive updates, which included the
initiation of our first registrational trial for HCC early
screening, new MRD partnerships, and recognition in multiple
influential publications,” remarked Mr. Sizhen Wang, co-founder and
CEO of Genetron Health. “Based on the continued enforcement of
“zero COVID” strategy in China, we anticipate a significantly
tougher operating environment in the fourth quarter. Despite this
short-term challenge, we remain laser focused on driving our
clinically differentiated pipeline of comprehensive precision
oncology diagnostics. Our long-term outlook remains unchanged as we
continue to execute on our strategies, and we anticipate multiple
data and trial updates from our key programs in the coming months.
In addition, the macro environment remains favorable for Genetron,
thanks to continued policy tailwinds in China that aim to improve
healthcare options for local citizens.”
Third Quarter 2021 Unaudited Preliminary
Financial ResultsTotal revenue for the third quarter of
2021 increased by 36.2% to RMB 152.5 million (US $23.7 million)
from RMB 112.0 million in the same period of 2020.
Diagnosis and monitoring revenue increased by 42.2% to RMB
144.3 million (US $22.4 million) in the third quarter of 2021 from
RMB 101.5 million in the same period of 2020. The increase was
primarily driven by the growth in the revenue generated from the
sale of both LDT & IVD products.
- Revenue generated from the provision of LDT services increased
by 30.2% to RMB 93.0 million (US $14.4 million) during the third
quarter of 2021 from RMB 71.4 million in the same period of 2020,
primarily driven by increased sales of HCC early screening tests.
LDT diagnostic tests sold in the third quarter 2021 totaled
approximately 5,900 units.
- Revenue generated from sales of IVD products increased by 70.5%
to RMB 51.3million (US $8.0 million) in the third quarter of 2021
from RMB 30.1 million in the third quarter of 2020. The increase
was driven by sales of the Genetron S5 instrument and 8-gene Lung
Cancer Assay (Tissue).
Contracted in-hospital
partners(as of the end of the period
indicated)
|
|
|
|
|
|
|
|
3Q20 |
4Q20 |
1Q21 |
2Q21 |
3Q21 |
|
IVD
In-hospital partners |
20 |
22 |
23 |
28 |
29 |
|
|
|
|
|
|
|
|
|
3Q20 |
4Q20 |
1Q21 |
2Q21 |
3Q21 |
|
Total
in-hospital partners(1) |
38 |
40 |
42 |
50 |
54 |
|
Note:(1) The
number of total in-hospital partners include both sales of LDT
services and IVD products. |
|
|
|
Revenue generated from development services
decreased by 21.4% to RMB 8.2 million (US $1.3 million) in the
third quarter of 2021, from RMB 10.4 million in the same period of
2020. The decrease was mainly due to the decline in sequencing
services, as the Company continued to focus on higher margin
biopharmaceutical services. Biopharmaceutical revenue continued to
grow compared to the same period of 2020.
Gross profit increased by 51.1% to RMB 105.2 million (US
$16.3 million) in the third quarter 2021 from RMB 69.6 million in
the same period of 2020. Gross margin improved to 69.0% for the
third quarter of 2021, compared to 62.2% in the same period of
2020, primarily due to higher gross margins for both the LDT and
IVD business lines.
Selling expenses increased by 56.3% to RMB 94.6
million (US $14.7 million) in the third quarter of 2021 from RMB
60.6 million in the same period of 2020. Selling expenses as a
percentage of revenues was 62.0% in the third quarter of 2021,
compared to 54.1% in the same period of 2020. The increase was
primarily driven by increased headcount to expand Genetron’s core
business as well as early screening sales teams.
Administrative expenses increased by 94.1% to
RMB 63.0 million (US $9.8 million) in the third quarter of 2021
from RMB 32.4 million in the same period of 2020. Administrative
expenses as a percentage of revenues increased to 41.3% in the
third quarter of 2021 from 29.0% in the third quarter of 2020. The
increase was mainly driven by higher headcount, professional fees,
IT expenses, and share-based compensation.
Research and development expenses increased by
61.7% to RMB 62.4 million (US $9.7 million) in the third quarter of
2021 from RMB 38.6 million in the same period of 2020. Research and
development expenses as a percentage of revenues increased to 40.9%
in the third quarter of 2021 from 34.4% in the same period of 2020.
The increases were driven by higher R&D headcount and related
expenses, as well as continued innovation efforts, including
product development and clinical trial activities.
Loss for the period was RMB 130.1 million (US
$20.2 million) for the three months ended September 30, 2021,
compared to RMB 48.0 million for the three months ended September
30, 2020.
Non-IFRS loss for the period, defined as loss
for the period excluding share-based compensation expenses, fair
value change and other loss of financial instruments with preferred
rights, was RMB109.9 million (US $17.1 million) for the three
months ended September 30, 2021, compared to RMB 43.7 million for
the three months ended September 30, 2020. Please refer to the
section in this press release titled "Non-IFRS Financial Measures"
for details.
Basic loss per share attributable to ordinary shareholders of
the Company was RMB 0.28 (US $0.04) for the third quarter of 2021,
compared with a basic loss per share attributable to ordinary
shareholders of the Company of RMB 0.11 for the same period of
2020.
Excluding share-based compensation expenses, fair value change
of financial instruments with preferred rights and other loss of
financial instruments with preferred rights, non-IFRS basic loss
per share attributable to ordinary shareholders of the Company was
RMB 0.24 (US $0.04) for the third quarter of 2021, compared with
non-IFRS basic loss per share attributable to ordinary shareholders
of the Company of RMB 0.10 for the same period of 2020.
Diluted loss per share attributable to ordinary shareholders of
the Company is equivalent to basic loss per share attributable to
ordinary shareholders of the Company. Each ADS represents of five
ordinary shares, par value US $0.00002 per share. Please refer to
the section in this press release titled "Non-IFRS Financial
Measures" for details.
As of September 30, 2021, cash and cash equivalents, restricted
cash and current financial assets at fair value through profit or
loss were RMB 1,005.3 million (US $156.0 million).
2021 Financial GuidanceBased on
the continued enforcement of the “zero COVID” strategy in China and
the resulting sustained restrictions across Genetron’s major
markets, the Company is revising its full year 2021 revenue
guidance to be around RMB 530 million, representing approximately
24.9% growth over the Company’s full year 2020 revenue.
Conference CallA conference
call and webcast to discuss the results will be held at 8:30 a.m.
U.S. Eastern Time on November 30, 2021 (or at 9:30 p.m. Beijing
Time on November 30, 2021). Interested parties may listen to the
conference call by dialing numbers below:
United
States: |
+1-332-208-9468 |
China Domestic: |
400-820-5286 |
Hong Kong: |
+852-3018-6771 |
International: |
+65-6713-5590 |
Conference ID: |
5848053 |
Participants are encouraged to dial into the
call at least 15 minutes in advance due to high call volumes.
A replay will be accessible through December 7,
2021 by dialing the following numbers:
United
States: |
+1-855-452-5696 |
International: |
+61-2-8199-0299 |
Conference ID: |
5848053 |
A simultaneous webcast of the conference call
will be available on the "News and Presentations" page of the
Investors section of the Company's website. A replay of the webcast
will be available for 30 days following the event. For more
information, please visit ir.genetronhealth.com.
Exchange Rate Information All
translations made in the financial statements or elsewhere in this
press release made from RMB into United States dollars (“US$”) are
solely for convenience and calculated at the rate of US$1.00=RMB
6.4434, representing the exchange rate as of September 30, 2021,
set forth in the H.10 statistical release of the U.S. Federal
Reserve Board. No representation is made that the RMB amounts could
have been, or could be, converted, realized or settled into US$ at
that rate, or at any other rate, on September 30, 2021.
Non-IFRS Financial Measures The
Company uses non-IFRS loss and non-IFRS loss per share attributable
to ordinary shareholders of the Company for the year/period, which
are non-IFRS financial measures, in evaluating its operating
results and for financial and operational decision-making purposes.
The Company believes that non-IFRS loss and non-IFRS loss per share
attributable to ordinary shareholders of the Company help identify
underlying trends in the Company's business that could otherwise be
distorted by the effect of certain expenses that the Company
includes in its loss for the year/period. The Company believes that
non-IFRS loss and non-IFRS loss per share attributable to ordinary
shareholders of the Company for the year/period provide useful
information about its results of operations, enhances the overall
understanding of its past performance and future prospects and
allows for greater visibility with respect to key metrics used by
its management in its financial and operational
decision-making.
Non-IFRS loss and non-IFRS loss per share
attributable to ordinary shareholders of the Company for the
year/period should not be considered in isolation or construed as
an alternative to operating profit, loss for the year/period or any
other measure of performance or as an indicator of its operating
performance. Investors are encouraged to review non-IFRS loss and
non-IFRS loss per share attributable to ordinary shareholders of
the Company for the year/period and the reconciliation to its most
directly comparable IFRS measures. Non-IFRS loss and non-IFRS loss
per share attributable to ordinary shareholders of the Company for
the year/period presented here may not be comparable to similarly
titled measures presented by other companies. Other companies may
calculate similarly titled measures differently, limiting their
usefulness as comparative measures to the Company's data. The
Company encourages investors and others to review its financial
information in its entirety and not rely on a single financial
measure.
Non-IFRS loss and non-IFRS loss per share
attributable to ordinary shareholders of the Company for the
year/period represent loss for the year/period excluding
share-based compensation expenses, fair value change of financial
instruments with preferred rights and other loss of financial
instruments with preferred rights (if applicable).
Please see the “Unaudited Non-IFRS Financial
Measures” included in this press release for a full reconciliation
of non-IFRS loss for the year/period to loss for the year/period
and non-IFRS loss per share attributable to ordinary shareholders
of the Company for the year/period to loss per share attributable
to ordinary shareholders of the Company for the year/period.
About Genetron Holdings
LimitedGenetron Holdings Limited (“Genetron Health” or the
“Company”) (Nasdaq: GTH) is a leading precision oncology platform
company in China that specializes in cancer molecular profiling and
harnesses advanced technologies in molecular biology and data
science to transform cancer treatment. The Company has developed a
comprehensive oncology portfolio that covers the entire spectrum of
cancer management, addressing needs and challenges from early
screening, diagnosis and treatment recommendations, as well as
continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit ir.genetronhealth.com.
Safe Harbor Statement This
press release contains forward-looking statements. These statements
are made under the “safe harbor” provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Statements that are not
historical facts, including statements about the Company’s beliefs
and expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties, and a number
of factors could cause actual results to differ materially from
those contained in any forward-looking statement. In some cases,
forward-looking statements can be identified by words or phrases
such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. Further
information regarding these and other risks, uncertainties or
factors is included in the Company’s filings with the SEC. All
information provided in this press release is as of the date of
this press release, and the Company does not undertake any duty to
update such information, except as required under applicable
law.
Investor Relations Contact US: Hoki Luk Head of
Investor Relations Email: hoki.luk@genetronhealth.com Phone:
+1 (408) 891-9255
Philip Trip TaylorVice President | Gilmartin
Groupir@genetronhealth.com
Media Relations ContactYanrong ZhaoGenetron
Healthyanrong.zhao@genetronhealth.com
Edmond LococoICREdmond.Lococo@icrinc.com Mobile: +86
138-1079-1408genetron.pr@icrinc.com
GENETRON HOLDINGS LIMITED
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF
LOSS
|
For the
three months ended |
|
For the nine months ended |
|
|
|
September 30, 2020 |
September 30, 2021 |
|
September 30,
2020 |
September 30, 2021 |
|
RMB’000 |
RMB’000 |
US$’000 |
|
RMB’000 |
RMB’000 |
US$’000 |
Revenue |
111,963 |
|
|
152,541 |
|
|
23,674 |
|
|
290,541 |
|
|
385,087 |
|
|
59,765 |
|
Cost of revenue |
(42,331 |
) |
|
(47,306 |
) |
|
(7,342 |
) |
|
(114,448 |
) |
|
(130,839 |
) |
|
(20,306 |
) |
|
|
|
|
|
|
|
|
Gross profit |
69,632 |
|
|
105,235 |
|
|
16,332 |
|
|
176,093 |
|
|
254,248 |
|
|
39,459 |
|
|
|
|
|
|
|
|
|
Selling expenses |
(60,558 |
) |
|
(94,625 |
) |
|
(14,686 |
) |
|
(175,000 |
) |
|
(242,812 |
) |
|
(37,684 |
) |
Administrative expenses |
(32,440 |
) |
|
(62,981 |
) |
|
(9,774 |
) |
|
(81,969 |
) |
|
(162,161 |
) |
|
(25,167 |
) |
Research and development expenses |
(38,556 |
) |
|
(62,364 |
) |
|
(9,679 |
) |
|
(96,030 |
) |
|
(168,500 |
) |
|
(26,151 |
) |
Net impairment losses on financial and contract
assets |
(1,107 |
) |
|
(10,437 |
) |
|
(1,620 |
) |
|
(2,097 |
) |
|
(23,741 |
) |
|
(3,684 |
) |
Other income/(loss) - net |
3,819 |
|
|
334 |
|
|
52 |
|
|
(513 |
) |
|
8,945 |
|
|
1,388 |
|
|
|
|
|
|
|
|
|
Operating expenses |
(128,842 |
) |
|
(230,073 |
) |
|
(35,707 |
) |
|
(355,609 |
) |
|
(588,269 |
) |
|
(91,298 |
) |
|
|
|
|
|
|
|
|
Operating loss |
(59,210 |
) |
|
(124,838 |
) |
|
(19,375 |
) |
|
(179,516 |
) |
|
(334,021 |
) |
|
(51,839 |
) |
|
|
|
|
|
|
|
|
Finance income |
12,772 |
|
|
482 |
|
|
75 |
|
|
11,062 |
|
|
1,712 |
|
|
265 |
|
Finance costs |
(1,560 |
) |
|
(5,791 |
) |
|
(898 |
) |
|
(3,997 |
) |
|
(5,022 |
) |
|
(779 |
) |
|
|
|
|
|
|
|
|
Finance income/(costs) - net |
11,212 |
|
|
(5,309 |
) |
|
(823 |
) |
|
7,065 |
|
|
(3,310 |
) |
|
(514 |
) |
|
|
|
|
|
|
|
|
Fair value loss of financial instruments with preferred
rights |
- |
|
|
- |
|
|
- |
|
|
(2,823,370 |
) |
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
Loss before income tax |
(47,998 |
) |
|
(130,147 |
) |
|
(20,198 |
) |
|
(2,995,821 |
) |
|
(337,331 |
) |
|
(52,353 |
) |
Income tax expense |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
Loss for the period |
(47,998 |
) |
|
(130,147 |
) |
|
(20,198 |
) |
|
(2,995,821 |
) |
|
(337,331 |
) |
|
(52,353 |
) |
|
|
|
|
|
|
|
|
Loss attributable to: |
|
|
|
|
|
|
|
Owners of the Company |
(47,998 |
) |
|
(128,974 |
) |
|
(20,016 |
) |
|
(2,995,821 |
) |
|
(333,548 |
) |
|
(51,766 |
) |
Non-controlling interests |
- |
|
|
(1,173 |
) |
|
(182 |
) |
|
- |
|
|
(3,783 |
) |
|
(587 |
) |
|
|
|
|
|
|
|
|
|
(47,998 |
) |
|
(130,147 |
) |
|
(20,198 |
) |
|
(2,995,821 |
) |
|
(337,331 |
) |
|
(52,353 |
) |
|
|
|
|
|
|
|
|
Loss per share attributable to ordinary shareholders of
the Company |
RMB |
|
|
RMB |
|
|
USD |
|
|
RMB |
|
|
RMB |
|
|
USD |
|
-Basic and diluted |
(0.11 |
) |
|
(0.28 |
) |
|
(0.04 |
) |
|
(12.02 |
) |
|
(0.73 |
) |
|
(0.11 |
) |
|
|
|
|
|
|
|
|
Loss per ADS attributable to ordinary shareholders of
the Company |
|
|
|
|
|
|
|
-Basic and diluted |
(0.53 |
) |
|
(1.40 |
) |
|
(0.22 |
) |
|
(60.10 |
) |
|
(3.63 |
) |
|
(0.56 |
) |
|
|
|
|
|
|
|
|
Shares used in loss
per share attributable to ordinary shareholders of the Company
computation: |
|
|
|
|
|
|
|
|
-Basic and diluted |
454,231,486 |
|
|
461,356,043 |
|
|
461,356,043 |
|
|
249,230,922 |
|
|
459,793,465 |
|
|
459,793,465 |
|
ADS used in loss per
ADS attributable to ordinary shareholders of the Company
computation: |
|
|
|
|
|
|
|
|
-Basic and diluted |
90,846,297 |
|
|
92,271,209 |
|
|
92,271,209 |
|
|
49,846,184 |
|
|
91,958,693 |
|
|
91,958,693 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GENETRON HOLDINGS LIMITED
UNAUDITED NON-IFRS FINANCIAL MEASURE
|
For the three months ended |
For the nine months ended |
|
|
September 30,
2020 |
September 30, 2021 |
September 30,
2020 |
September 30, 2021 |
|
RMB’000 |
RMB’000 |
US$’000 |
RMB’000 |
RMB’000 |
US$’000 |
|
|
|
|
|
|
|
Loss
for the period |
(47,998 |
) |
|
(130,147 |
) |
|
(20,198 |
) |
|
(2,995,821 |
) |
|
(337,331 |
) |
|
(52,353 |
) |
Adjustments: |
|
|
|
|
|
|
Share-based compensation |
4,268 |
|
|
20,246 |
|
|
3,141 |
|
|
19,222 |
|
|
42,000 |
|
|
6,518 |
|
Fair value loss of financial
instruments with preferred rights |
- |
|
|
- |
|
|
- |
|
|
2,823,370 |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
Non-IFRS Loss |
(43,730 |
) |
|
(109,901 |
) |
|
(17,057 |
) |
|
(153,229 |
) |
|
(295,331 |
) |
|
(45,835 |
) |
|
|
|
|
|
|
|
Attributable to: |
|
|
|
|
|
|
Owners of the Company |
(43,730 |
) |
|
(108,728 |
) |
|
(16,875 |
) |
|
(153,229 |
) |
|
(291,548 |
) |
|
(45,248 |
) |
Non-controlling interests |
- |
|
|
(1,173 |
) |
|
(182 |
) |
|
- |
|
|
(3,783 |
) |
|
(587 |
) |
|
|
|
|
|
|
|
|
(43,730 |
) |
|
(109,901 |
) |
|
(17,057 |
) |
|
(153,229 |
) |
|
(295,331 |
) |
|
(45,835 |
) |
|
|
|
|
|
|
|
Non-IFRS loss per share
attributable to ordinary shareholders of the
Company |
RMB |
|
|
RMB |
|
|
USD |
|
|
RMB |
|
|
RMB |
|
|
USD |
|
-Basic and diluted |
(0.10 |
) |
|
(0.24 |
) |
|
(0.04 |
) |
|
(0.61 |
) |
|
(0.63 |
) |
|
(0.10 |
) |
|
|
|
|
|
|
|
Non-IFRS
loss per ADS(5 ordinary shares equal to 1 ADS)
attributable to ordinary shareholders of the
Company |
|
|
|
|
|
|
-Basic and diluted |
(0.48 |
) |
|
(1.18 |
) |
|
(0.18 |
) |
|
(3.07 |
) |
|
(3.17 |
) |
|
(0.49 |
) |
|
|
|
|
|
|
|
Shares used in
non-IFRS loss per share attributable to ordinary
shareholders of the Company
computation: |
|
|
|
|
|
|
-Basic and diluted |
454,231,486 |
|
|
|
461,356,043 |
|
|
461,356,043 |
|
|
249,230,922 |
|
|
459,793,465 |
|
|
459,793,465 |
|
|
|
|
|
|
|
|
ADS used
in non-IFRS loss per ADS attributable to ordinary
shareholders of the Company
computation: |
|
|
|
|
|
|
-Basic and diluted |
90,846,297 |
|
|
92,271,209 |
|
|
92,271,209 |
|
|
49,846,184 |
|
|
91,958,693 |
|
|
91,958,693 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GENETRON HOLDINGS LIMITEDUNAUDITED
REVENUE AND SEGMENT INFORMATION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnosis and
monitoring |
|
Diagnosis and
monitoring |
|
Development services |
|
Total |
- provision of LDT services |
- sale of IVD products |
|
RMB’000 |
|
RMB’000 |
|
RMB’000 |
|
RMB’000 |
|
|
|
|
|
|
|
|
Three months ended September 30,
2020 |
|
|
|
|
|
|
Revenue |
71,406 |
|
30,110 |
|
10,447 |
|
111,963 |
Segment profit |
49,212 |
|
18,439 |
|
1,981 |
|
69,632 |
|
|
|
|
|
|
|
|
Three months ended September 30,
2021 |
|
|
|
|
|
|
Revenue |
92,993 |
|
51,338 |
|
8,210 |
|
152,541 |
Segment profit |
65,022 |
|
39,159 |
|
1,054 |
|
105,235 |
|
|
|
|
|
|
|
|
Nine months ended September 30,
2020 |
|
|
|
|
|
|
Revenue |
194,754 |
|
67,468 |
|
28,319 |
|
290,541 |
Segment profit |
130,961 |
|
43,827 |
|
1,305 |
|
176,093 |
|
|
|
|
|
|
|
|
Nine months ended September 30,
2021 |
|
|
|
|
|
|
Revenue |
251,959 |
|
110,431 |
|
22,697 |
|
385,087 |
Segment profit |
175,723 |
|
75,693 |
|
2,832 |
|
254,248 |
|
|
|
|
|
|
|
|
GENETRON HOLDINGS LIMITED
UNAUDITED CONDENSED CONSOLIDATED BALANCE
SHEETS
|
|
As
at
December
31,2020 |
|
As
at September
30,2021 |
|
|
RMB’000 |
|
RMB’000 |
|
US$’000 |
ASSETS |
|
|
|
|
|
|
Non-current assets |
|
|
|
|
|
|
Property, plant and equipment |
|
76,891 |
|
85,441 |
|
13,260 |
Right-of-use assets |
|
59,706 |
|
50,938 |
|
7,905 |
Intangible assets |
|
12,265 |
|
15,104 |
|
2,344 |
Financial assets at fair value through profit or loss |
|
19,609 |
|
37,005 |
|
5,743 |
Prepayments |
|
15,362 |
|
23,765 |
|
3,688 |
|
|
|
|
|
|
|
Total non-current assets |
|
183,833 |
|
212,253 |
|
32,940 |
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
Inventories |
|
24,971 |
|
41,657 |
|
6,465 |
Contract assets |
|
1,112 |
|
2,217 |
|
344 |
Other current assets |
|
36,500 |
|
26,513 |
|
4,115 |
Trade receivables |
|
164,592 |
|
279,725 |
|
43,413 |
Other receivables and prepayments |
|
42,420 |
|
83,188 |
|
12,911 |
Amounts due from related parties |
|
214 |
|
453 |
|
70 |
Financial assets at fair value through profit or
loss |
140,294 |
|
187,398 |
|
29,084 |
Derivative financial instruments |
196 |
|
673 |
|
104 |
Restricted cash |
- |
|
2,800 |
|
435 |
Cash and cash equivalents |
|
1,375,766 |
|
815,142 |
|
126,508 |
|
|
|
|
|
|
|
Total current assets |
|
1,786,065 |
|
1,439,766 |
|
223,449 |
|
|
|
|
|
|
|
Total assets |
|
1,969,898 |
|
1,652,019 |
|
256,389 |
|
|
|
|
|
|
|
GENETRON HOLDINGS LIMITED
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(CONTINUED)
|
|
As
at
December
31,2020 |
As
at September
30,2021 |
|
|
RMB’000 |
RMB’000 |
US$’000 |
|
|
|
|
|
LIABILITIES |
|
|
|
|
Non-current liabilities |
|
|
|
|
Borrowings |
|
5,493 |
|
|
- |
|
|
- |
|
Lease liabilities |
|
43,016 |
|
|
32,694 |
|
|
5,074 |
|
Other non-current liabilities |
|
- |
|
|
8,354 |
|
|
1,297 |
|
|
|
|
|
|
Total non-current liabilities |
|
48,509 |
|
|
41,048 |
|
|
6,371 |
|
|
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
Trade payables |
|
34,071 |
|
|
38,907 |
|
|
6,038 |
|
Contract liabilities |
|
8,417 |
|
|
12,640 |
|
|
1,962 |
|
Other payables and accruals |
|
111,164 |
|
|
119,399 |
|
|
18,530 |
|
Amounts due to related parties |
|
24 |
|
|
350 |
|
|
54 |
|
Borrowings |
|
58,583 |
|
|
27,595 |
|
|
4,283 |
|
Lease liabilities |
|
16,585 |
|
|
19,640 |
|
|
3,048 |
|
Derivative financial instruments |
|
- |
|
|
1,702 |
|
|
264 |
|
|
|
|
|
|
Total current liabilities |
|
228,844 |
|
|
220,233 |
|
|
34,179 |
|
|
|
|
|
|
Total liabilities |
|
277,353 |
|
|
261,281 |
|
|
40,550 |
|
|
|
|
|
|
Net assets |
|
1,692,545 |
|
|
1,390,738 |
|
|
215,839 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SHAREHOLDERS’ EQUITY |
|
|
|
|
Equity attributable to owners of the
Company |
|
|
Share capital |
|
59 |
|
|
60 |
|
|
9 |
|
Share premium |
|
6,657,562 |
|
|
6,702,347 |
|
|
1,040,188 |
|
Other reserves |
|
(24,701 |
) |
|
(44,784 |
) |
|
(6,950 |
) |
Accumulated losses |
|
(4,940,375 |
) |
|
(5,273,923 |
) |
|
(818,500 |
) |
|
|
|
|
|
|
|
1,692,545 |
|
|
1,383,700 |
|
|
214,747 |
|
|
|
|
|
|
Non-controlling interests |
|
- |
|
|
7,038 |
|
|
1,092 |
|
|
|
|
|
|
Total shareholders’ equity |
1,692,545 |
|
|
1,390,738 |
|
|
215,839 |
|
|
|
|
|
|
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024